top of page

Providence RX Health

Disclosures and Disclaimers


Providence RX Health, LLC is a patient management telehealth platform that works with independent physicians and practitioners who provide services utilizing the Providence RX Telehealth Platform. Providence RX Health does not directly provide medical or pharmacy services and payment does not guarantee the writing or dispensing of a prescription. Medical services are provided by a network of individual medical professionals. The information provided on this website is for informational purposes and not a substitute for professional medical advice, diagnosis, or treatment. If you have questions or concerns about your health, please talk to your doctor. This site is an advertisement for services and not any specific medication.

Results from the ProvidenceRX Program may vary based on starting weight and Program adherence.  Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone.  The use of such medications offered in the ProvidenceRX Program typically result in 1 to 2 lb. per week weight loss* in the first 4 weeks, involving a healthy diet with a calorie deficit and exercise changes. 

*Based on the average weight loss in three 68-week clinical trials of patients without diabetes who reached and maintained a dose of 2.4mg per week of GLP-1 treatment, along with a reduced calorie diet and increased physical activity.

Wegovy® is FDA-approved for weight loss.  Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss.  Mounjaro® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss management in people who are obese, or those who are overweight and have weight-related health problems (such as high blood pressure or pre-diabetes). Zepbound TM is FDA-approved for weight loss.  The trademarks, service marks, tradenames (Wegovy,® Ozempic,® Mounjaro,® and Zepbound TM) and products displayed on this Internet site are protected and belong to their respective owners.

GLP-1 receptor agonists—including semaglutide, liraglutide, dulaglutide and tirzepatide—have been prescribed (on-and-off label) for weight management, including obesity, along with a reduced caloric diet and increased physical activity.  Take precaution with and read all warmings concerning GLP-1s, as they may cause serious side effects, including the risk of thyroid c-cell tumors.  Do not use if you or your family have a history of a type of thyroid cancer called MTC (medullary thyroid carcinoma) or MEN 2 (multiple endocrine neoplasia syndrome). See Important Safety Information about these medications.

bottom of page